BNET Industries
Last Fiscal Year Sales:$1.0B
- Private
- US
Dow Jones Description
Injectable Monoclonal Antibody-Based Pharmaceuticals Mfr & Developer for Cardiovascular, Infectious & Autoimmune Diseases
CFO & Vice President
Richard A. BierlyNumber of Employees 3,000
Peer Companies
NAICS Code In-Vitro Diagnostic Substance Manufacturing: 325413
Recent Events
-
2009 Brought the Biggest Patent Infringement Verdict in History: $1.67 Billion
-
Litigator of the Week: Dianne Elderkin of Woodcock Washburn
News & Analysis
Filter by
centocor inc. and fda - All News and Analysis
Ustekinumab approval delayed by FDA
- 2009-02-01
The Food and Drug Administration has requested more information about ustekinumab before it is approved for treating moderate to severe plaque psoriasis, according to Centocor Inc., the manufacturer of the monoclonal antibody. In a statement issued in December, the company reported that the information requested by the FDA includes...
Neurochem Inc. Posts Q1 Results.
- 2007-05-10
M2 PRESSWIRE-10 May 2007-InvestorInstantMessaging: Neurochem Inc. Posts Q1 ResultsC1994-2007 M2 COMMUNICATIONS LTD RDATE:10052007 InvestorIM has been created as a tool for the average investor. The idea is simple, a website where the world can communicate. Do you have a stock related...
Neurochem Inc. Added to Bellwether Watch List.
- 2007-05-10
M2 PRESSWIRE-10 May 2007-Biotech News: Neurochem Inc. Added to Bellwether Watch ListC1994-2007 M2 COMMUNICATIONS LTD RDATE:10052007 Neurochem develops biopharmaceutical drugs, primarily for disorders originating in the central nervous system. Current areas of research focus include Alzheimer's disease, certain types of stroke,...
FDA approves Remicade for psoriasis
- 2006-11-01
Centocor, Inc, recently announced that the FDA has approved infliximab for the treatment of chronic severe plaque psoriasis. Remicade is an antitumor necrosis factor alpha that is administered directly by caregivers as an intravenous infusion. The initial recommended dose for this newly approved indication is 5 mg/kg, followed by subsequent...
FDA approves Centocor’s Remicade for psoriasis
- 2006-09-27
Centocor Inc., of Horsham, said today that U.S. regulators have approved its rheumatoid arthritis drug, Remicade, to treat the dermatological condition, psoriasis. The biotechnology subsidiary of Johnson & Johnson said eight out of 10 patients treated with Remicade, known by the chemical name infliximab, had a 75 percent improvement in...
New Remicade indication
- 2006-08-28
The FDA has expanded the indication for Centocor Inc.'s Remicade. It can now be used for inhibiting the progression of structural damage and improving physical function in patients with psoriatic arthritis.
Solodyn, Remicade
- 2006-07-01
Solodyn (minocycline extended release tablets, Medicis) The Food and Drug Administration approved Solodyn minocycline extendedrelease tablets for treatment of inflammatory nonnodular moderate to severe acne vulgaris in patients 12 years of age and older. * Recommended Dosage: Prescribe 1 mg/kg daily for 12 weeks. Solodyn comes in...
FDA OKs Remicade for use in kids with Crohn’s
- 2006-05-19
Centocor Inc., of Horsham, said today U.S. regulators have approved its Remicade rheumatoid arthritis drug to treat Crohn's disease in children. The Food and Drug Administration said in a statement on the agency's Web site that there have been no satisfactory treatments for children with moderate to severe Crohn's...
FDA fast-tracks Centocor drug for pediatric Crohn’s
- 2006-04-04
Centocor Inc., the biotechnology subsidiary of Johnson & Johnson, said today the Food and Drug Administration granted priority review to the company's rheumatoid arthritis treatment Remicade for pediatric Crohn's disease. The Horsham company said a late-stage Phase 3 clinical study showed "unprecedented efficacy" in treating children with moderate to...
Remicade eyed for psoriatic arthritis by FDA
- 2005-01-01
The U.S. Food and Drug Administration has accepted Centocor Inc.'s application to approve infliximab Remicade for the treatment of psoriatic arthritis. Already approved for use in rheumatoid arthritis and Crohn's disease in North America, the European Union, and Japan, infliximab was recently approved for use in psoriatic arthritis by...
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Richard A. Bierly | CFO & Vice President |
| Daniel Everitt | Vice President of Clinical Pharmacology and Global Pharmacovigilance |
| Ronald E. Schmid | Vice President, Corp Communications |
| William R Tolbert | Vice President |
| David P. Holveck | Director |
| Organization | Position | Status |
|---|---|---|
| Centocor, Inc. | CFO & Vice President | Current |
| Organization | Position | Status |
|---|---|---|
| Centocor, Inc. | Vice President of Clinical Pharmacology and Global Pharmacovigilance | Current |
| Institute for Oneworld Health | Board of Directors | Current |
| SmithKline Beecham Corporation | Director of Clinical Pharmacology | Former |
| Neuroscience, Inc | Group Director | Former |
| Organization | Position | Status |
|---|---|---|
| Centocor, Inc. | Vice President, Corp Communications | Current |
| Organization | Position | Status |
|---|---|---|
| Advanced Tissue Sciences, Inc. | Vice President | Current |
| Centocor, Inc. | Vice President | Current |
| Invitron Limited | Vice President | Current |
| Merchant-Taylor International, Inc | Senior Associate | Current |
David P. Holveck was appointed President, Chief Executive Officer, and a Director of Endo in April 2008. Prior to joining Endo, Mr. Holveck was President of Johnson & Johnson Development Corporation and Vice President, Corporate Development of Johnson & Johnson since 2004. Mr. Holveck joined Johnson & Johnson as a company Group Chairman in 1999, following the acquisition of Centocor, Inc., by Johnson & Johnson. Mr. Holveck was Chief Executive Officer of Centocor, Inc., at the time of the acquisition. Mr. Holveck joined Centocor in 1983 and progressed through various executive positions. In 1992, he assumed the role of President and Chief Operating Officer and later that year was named President and Chief Executive Officer. Prior to joining Centocor, he held positions at General Electric Company, Corning Glass Works, and Abbott Laboratories. Mr. Holveck is a member of the Board of Trustees for the Fund for West Chester University and the Board of Directors of the Eastern Technology Council as well as the Board of Directors of Light Sciences Oncology, Inc.
| Organization | Position | Status |
|---|---|---|
| Endo Pharmaceuticals Holdings Inc. | President & Chief Executive Officer | Current |
| Johnson & Johnson Development Corp. | Vice President, Corporate Development | Current |
| Tengion, Inc. | Current | |
| Biotechnology Industry Organization | board member | Current |
| Eastern Technology Council | Board Member | Current |
| Centocor, Inc. | Director | Current |
| University City Science Center | Board of Directors | Current |
| Light Sciences Oncology, Inc. | Board of Directors | Current |
| Liberty Science Center, Inc. | Board Member | Current |
| Endo Pharmaceuticals Holdings Inc. | Board of Directors | Current |
| Centocor, Inc. | Chief Executive Officer | Former |
| Johnson & Johnson | President, Corporate Development | Former |
| Centocor, Inc. | president | Former |
| Centocor, Inc. | chief operating officer | Former |
| General Electric Company | Team Member | Former |
| Abbott Laboratories | Team Member | Former |
| Corning Glass Works | Team Member | Former |
| Johnson & Johnson Development Corp. | President | Former |
| The Group Inc. | Chairman | Former |
| Johnson & Johnson Development Corp. | Company Group Chairman | Former |
| Johnson & Johnson | Company Group Chairman | Former |
| West Chester University | B.S. Degree In Education | Former |
Executive News
-
Endo Pharmaceuticals Introduces Valstar (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer
-
FDA extends review on Endo drug
-
Endo Pharmaceuticals (ENDP) Says FDA Extends Review Date for Testosterone Treatment 9/3/2009
-
Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive...
-
Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer
-
Endo Pharmaceuticals Gives Update on Regulatory Status of Testosterone Undecanoate...
-
Endo Pharmaceuticals Gives Update on Regulatory Status of Testosterone Undecanoate for Men with Hypogonadism
-
FDA taking more time to review Endo hypogonadism drug
-
Endo partners with ProStrakan to market testosterone transdermal gel
-
Endo to commercialize Fortesta in the U.S.
-
Endo licenses ProStrakan's testosterone gel Fortesta in US for up to $210 million
-
Endo buys rights to ProStrakan testosterone replacement gel Fortesta
-
Endo In Deal To Sell ProStrakan's Testosterone Gel In US
-
Endo Pharmaceuticals to Partner With ProStrakan to Commercialize FORTESTA(TM) in the U.S.
-
Biotech 2009 to Feature Endo Pharmaceuticals President and CEO, David P. Holveck, as Dinner...
-
Endo Pharmaceuticals's COO resigns
-
Endo Pharmaceuticals (ENDP) Announces Resignation of Chief Operating Officer
-
Endo Pharmaceuticals Announces Resignation of Chief Operating Officer
-
Endo Pharmaceuticals Announces Resignation of Chief Operating Officer
Industry Transcripts by Seeking Alpha
-
Neogen Corporation F2Q10 (Qtr End11/30/09) Earnings Call Transcript
on Dec 18, 2009about NEOG
-
Schiff Nutrition International, Inc. F2Q10 (Qtr End 11/30/09) Earnings Call Transcript
on Dec 17, 2009about WNI
-
Martek Biosciences Corporation F4Q09 (Qtr End 10/31/09) Earnings Call Transcript
on Dec 16, 2009about MATK
-
Peregrine Pharmaceuticals Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Dec 10, 2009about PPHM
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
Glass Door
Centocor
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
Presented by American Express